152
Views
10
CrossRef citations to date
0
Altmetric
Review

Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?

, &
Pages 243-250 | Published online: 09 Jan 2014
 

Abstract

The 21-gene recurrence score (RS) is a gene expression profile assay currently endorsed for use in patients with endocrine-sensitive node-negative breast cancers. The RS has been shown to augment current ‘prognostic’ and ‘predictive’ assessments of relapse risk and chemotherapy benefits, respectively, and lead to significant change in oncologists’ recommendations for adjuvant chemotherapy, with an overall reduction in chemotherapy utilization. The RS (Oncotype DX®) is marketed by Genomic Health Inc. (CA, USA) and currently retails for approximately US$4290 per patient. Like all novel tests/therapies, however, these upfront costs should be examined in the context of all its clinical benefits through cost–effectiveness or cost–utility evaluations. This review highlights the clinical evidence supporting RS testing for patients with endocrine-sensitive node-negative breast cancers, and examines all published economic evaluations that examined its ‘value for money’ in this setting.

Financial & competing interests disclosure

The authors have previously conducted an economic evaluation of the recurrence score in node-negative and node-positive breast cancer, supported by the Canadian Breast Cancer Foundation – Atlantic Chapter, which is discussed in this review. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 493.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.